Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FARVET's Chicken Anemia Virus (CAV) vaccine is a live-attenuated, lyophilized viral vaccine derived from the FAR-0023-17 strain. It is specifically developed for the prevention of Chicken Infectious Anemia (CIA), a disease caused by the Gyrovirus genus of the Anelloviridae family. The vaccine works by inducing active immunity in chickens, typically administered to breeders to provide maternal antibodies to their progeny or to young birds to prevent clinical disease. The FAR-0023-17 strain is a specific isolate used by FARVET to ensure high immunogenicity and protection against local and international strains of the virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chicken anemia virus strain FAR-0023-17 vaccine.